Comparative Pharmacology
Head-to-head clinical analysis: AMOXICILLIN CLAVULANATE versus VERSAPEN K.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMOXICILLIN CLAVULANATE versus VERSAPEN K.
Amoxicillin-Clavulanate vs VERSAPEN-K
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and autolysin inhibitors. Clavulanate is a beta-lactamase inhibitor that binds to and inactivates beta-lactamases, protecting amoxicillin from hydrolysis.
VERSAPEN-K (hetacillin potassium) is a prodrug that is hydrolyzed to ampicillin, which inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and disrupting peptidoglycan cross-linking.
500 mg/125 mg orally every 8 hours or 875 mg/125 mg orally every 12 hours; intravenous: 1 g/0.2 g every 8 hours.
250-500 mg intramuscularly or intravenously every 6 hours for moderate infections; 1-2 g every 6 hours for severe infections.
None Documented
None Documented
Amoxicillin: ~1-1.3 hours in adults with normal renal function; Clavulanate: ~1 hour. Both prolonged in renal impairment (amoxicillin up to 7-20 hours with CrCl <10 mL/min).
0.8-1.5 hours in adults with normal renal function (prolonged to 6-20 hours in severe renal impairment; dosing adjustment required when CrCl <30 mL/min).
Amoxicillin: ~60% renal as unchanged drug via glomerular filtration and tubular secretion; Clavulanate: ~30-50% renal as metabolites and unchanged, remainder fecal. Approximately 50-70% of total dose excreted renally within 6 hours.
Renal: 60-80% unchanged via glomerular filtration and tubular secretion; biliary: 15-20% as active drug; fecal: <5%.
Category C
Category C
Penicillin Antibiotic + Beta-Lactamase Inhibitor
Penicillin Antibiotic